Bharat Book

Multiple Myeloma Treatments: World Drug Industry and Market 2013-2023

Press Release   •   Dec 28, 2013 11:57 IST

Dec 28, 2013 : Bharat Book Bureau presents the new report, on ''Multiple Myeloma Treatments: World Drug Industry and Market 2013-2023"explains the potential of its market, helping you stay ahead.

Myeloma medicines - now discover R&D trends, opportunities, and potential revenues

What are the commercial prospects for treating multiple myeloma? Visiongain's updated report gives you predictions, helping you stay ahead. There you see financial results, technological developments, opportunities, and commercial outlooks.

In that new analysis you discover sales forecasts to 2023 at overall world market, submarket, product, and national level for those drugs. You also assess technologies, competition, and progress for treating that cancer. There find data and potentials.

Read on to explore those products and see what their future market could be worth.

Forecasts to 2023 and other information to benefit your research and analysis

Besides revenue predictions to 2023, our report gives you recent results, growth rates, and market shares. There you discover original analysis, seeing outlooks for business and developments (R&D). You also get 64 tables, 57 charts, and two interviews.

Assessment of that medical industry, showing data you need

In that study you hear what's happening for those anti-cancer medicines, learning where needs and money lie. Now see how you and your organisation can gain.

Avoid falling behind or losing influence. Instead discover information you need to stay ahead. Our study assesses those pharmaceuticals for blood cancers (haematological malignancies), helping you save time and benefit your research, analyses, and decisions.

The following sections show, then, what you get in that new investigation.

Forecasting of the world market and segments for that cancer therapy

Discover in our report overall world drug revenue to 2023 for multiple myeloma. You also see individual revenue predictions for five therapeutic submarkets at world level:
• Immunomodulators
• Proteasome inhibitors
• Monoclonal antibodies (mAbs)
• Kinase inhibitors
• Other agents.

How will sales of those therapies expand? Which drug classes will generate most money? There you assess prospects for revenue growth, seeing where you can benefit from the treatment of multiple myeloma (plasma cell myeloma or Kahler's disease).

You also discover forecasts by agent, seeing how they can succeed.

Predictions for myeloma-treating products - find what revenues are possible

How will those cancer-treating drugs perform to 2023 at world level? Our study forecasts myeloma sales of six top brands and four expected medicines, including these:
• Revlimid
• Velcade
• Thalomid
• Zometa
• Pomalyst
• Elotuzumab.

There you find each agent's potential. You see what's happening, then, understanding challenges, trends, competitors, and opportunities.

You also find geographical predictions.

National markets - where will highest revenues and sales growth occur?

In developed and developing countries, multiple myeloma therapies will give opportunities to pharmaceutical companies. You see where and how, from 2013, understanding potentials.

In our report you find individual revenue forecasts to 2023 for 11 national markets:
• United States (US)
• Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
• BRIC countries - Brazil, Russia, India, and China.

There you find countries with highest revenues and predicted sales growth. Our work explains. Discover the future of those products, hearing about progress in that healthcare field and seeing what it means.

There you assess trends in oncology and tackling those diseases.

Issues affecting developers, producers, and sellers of myeloma-treating medicines

Our study explains forces affecting that industry and market from 2013, including these:
• Therapy by induction, maintenance, and salvage methods
• Research and development (R&D) for those blood and bone marrow disorders
• Governmental support for developing and marketing therapies
• Prospects and capabilities of companies investigating that oncology.

There you assess developments, finding advances and outlooks for business. Discover what the present and future hold.

Companies and overall 2017 market value - how high can its revenues go?

From 2013, myeloma treatments hold potential for investments, medical advances, and higher revenues. Our analysis predicts that overall world market will reach $11.5bn in 2017, expanding to 2023.

That work shows you what technologies and organisations hold greatest potential. In particular, you explore these companies:
• Celgene
• Johnson & Johnson (J&J)
• Takeda
• Novartis
• Bristol-Myers Squibb
• Onyx Pharmaceuticals.

Table of Contents: 
1. Executive Summary
1.1 What This Report Covers
1.2 Multiple Myeloma: World Drug Market Overview 2013-2023
1.3 Chapter Outlines
1.4 Research and Analysis Methods

2. Introduction to Multiple Myeloma and its Treatment
2.1 What is Multiple Myeloma?
2.2 What Are Plasma Cells?
2.3 What Causes Multiple Myeloma?
2.4 Signs and Symptoms of the Disease
2.5 Demographic Risk Variation in Multiple Myeloma
2.6 Stages of the Disease
2.6.1 The Durie-Salmon Staging System and the International Staging System
2.7 Treatment of Multiple Myeloma
2.7.1 Induction Therapy
2.7.2 Maintenance Therapy
2.7.3 Salvage Therapy
2.8 Present and Future Options for Treating Multiple Myeloma: Summary

3. The World Multiple Myeloma Drug Treatment Market, 2013-2023
3.1 The World Multiple Myeloma Drug Treatment Market in 2012
3.2 Multiple Myeloma Drug Treatment: Overarching Market Forecast 2013-2023
3.3 World Multiple Myeloma Drug Treatment Market by Therapeutic Subclass: Comparison of Revenue and Market Share, 2018 and 2023
3.4 The World Multiple Myeloma Drug Treatment Market by Therapeutic Subclass: Grouped Revenue Forecasts, 2013-2023
3.5 Immunomodulators for Multiple Myeloma: Dominating the Market Throughout the Forecast Period
3.5.1 Immunomodulators: Revenue Forecast 2013-2023
3.6 Proteasome Inhibitors: A Cornerstone in Multiple Myeloma Drug Treatment
3.6.1 Proteasome Inhibitors: Revenue Forecast 2013-2023
3.7 Monoclonal Antibodies: Market Launch Anticipated in 2015
3.7.1 Monoclonal Antibodies: Revenue Forecast 2013-2023
3.8 Kinase Inhibitors: A Class of Advanced Cancer Medications
3.8.1 Kinase Inhibitors: Revenue Forecast 2013-2023
3.9 Summary: Growth of the Multiple Myeloma Drug Treatment Market, 2013-2023

For more information kindly visit :

Related link :

About Bharat Book Bureau:

Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.

In case the reports don't match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.

Contact us at :

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Follow us on twitter: 
Follow us on linked in : 
Our Blog : 

Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.